Evaxion and pennsylvania state university publish preclinical data validating our ai-based viral vaccine discovery platform

Copenhagen, denmark, april 13, 2023 (globe newswire) -- evaxion biotech a/s (nasdaq: evax), a clinical-stage biotechnology company specializing in ai-powered immunotherapies, announces the successful publication in frontiers of immunology of preclinical data demonstrating the effectiveness of its proprietary ai-driven viral vaccine discovery platform. the presented preclinical study was conducted in collaboration with associate professor girish kirimanjeswara, pennsylvania state university, us.
EVAX Ratings Summary
EVAX Quant Ranking